Progress on the Research and development of Dengue Vaccine

Abstract

Dengue fever is an infectious disease transmitted by Aedes mosquitoes caused by the dengue virus, and there are four serotypes. Each serotype acts as an independent infectious agent. Dengue illness can range from mild illness to life-threatening bleeding. Dengue fever is a growing health concern for up to a third of the world's population. Currently, there is no effective anti-dengue drug, and the treatment of severe dengue relies on intravenous fluid management and pain relief drugs. Despite decades of trying, the world already has a dengue vaccine licensed in many countries, but restrictions and conditions on its use have prevented its use. An effective dengue vaccine should be a quadrivalent vaccine that can protect against all four serotypes of dengue virus. Although inactivated vaccines are relatively safe, due to the disadvantages of low immune response, poor endurance, and prone to ADE, no significant progress has been made so far. The attenuated live vaccine has the advantages of strong immune response similar to wild strains, including cellular and humoral immune response, and immune persistence. It is the focus of current development and has made great progress. A review of live attenuated vaccines.